Branch Therapeutics, a University of Arizona startup co-founded by BIO5 members Christopher Hulme and Curtis Thorne, has received $4 million in seed funding to advance its development of targeted therapies for cancer and other diseases.

BIO5 member Mohammed Hassan is leading groundbreaking work on the development of the world's first phototransistor capable of operating at petahertz speeds under ambient conditions. Petahertz refers to a frequency of one million billion cycles per second, representing a significant leap in speed and performance.

BIO5 member Philipp Gutruf and his team at the University of Arizona have developed a new class of wearable devices designed to monitor health for longer periods without recharging.

BIO5 member Jeff Burgess and University of Arizona Health Sciences researchers found that health care workers and firefighters have higher levels of PFAS in their blood than the general population.

Biochemistry major Gavin Arnold is taking advantage of undergraduate University of Arizona research opportunities by conducting research with BIO5 member Ying-Hui Chou on using brain stimulation treatment to improve patients' cognitive abilities.

From exploring plant phenomics to developing 3D images of plants, Dr. Alexander Bucksch is reimagining how we study them to revolutionize agriculture.

Guests experienced the collaborative nature of research through conversations, hands-on demos, and real-world applications at the annual public event.

At an annual community event in early April, attendees heard from five accomplished University of Arizona researchers from diverse scientific disciplines during a series of intimate fireside chats. Read snapshots of these conversations.

Multiple BIO5 members lead the BEAMS study, investigating how early-life environmental exposures across the U.S.-Mexico border impact asthma risk.

BIO5 Members Julie Ledford, Josef Vagner, Stefano Guerra, and Michael D.L. Johnson co-developed an innovative inhaled asthma/COPD therapy licensed to Aspiro Therapeutics.